Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents
Tarunjit Singh, Linda Cuomo, Martin Cohen, Hasan A. Ahmad and Wilbert S. Aronow
Affiliation: Cardiology Division, Department of Medicine, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA.
Dual antiplatelet therapy (DAPT) with a thienopyridine and aspirin has been the standard of care post coronary
stent implantation. DAPT has been shown to reduce the risk of stent thrombosis (ST) and complications of myocardial
infarction and death after placement of a drug-eluting stent (DES) and bare-metal stent (BMS).This article reviews the
available clinical efficacy and safety data of antiplatelet therapies. The aim of this review is to highlight not only the
importance of antiplatelets in the prevention of early and late thrombosis but also emphasize the importance of newer
more potent antiplatelet agents and their role in the setting of clopidogrel resistance. MEDLINE, and EMBASE were
searched for studies related to the clinical efficacy and safety of antiplatelet therapy after DES and BMS placement using
the terms dual antiplatelet therapy, thienopyridine, aspirin, clopidogrel, prasugrel, ticagrelor,elinogrel, bare-metal stents,
drug-eluting stent, stent thrombosis and myocardial infarction.
Keywords: Antiplatelet therapy, bare-metal stents, drug-eluting stents, percutaneous coronary intervention, PHARMACOKINETICS, PHARMACODYNAMICS, PLATELET PHYSIOLOGY, Antiplatelet Therapy, Clopidogrel, Aspirin, Prasugrel, GLYCOPROTEIN IIb/IIIa INHIBITORS
Rights & PermissionsPrintExport